You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Bio-Rad's year-over-year Q3 revenue increase was driven primary by sales of PCR and Droplet Digital PCR products due to the COVID-19 pandemic.
Shares of the Boulder, Colorado-based firm will begin trading on the Nasdaq today under ticker symbol "BDSX" at $18 per share.
The overall revenue decrease was buoyed by 19 percent year-over-year growth in Life Science segment revenues due to strong PCR-related sales.
The triplex assay can be used on the firm's QX200 or QXDx Droplet Digital PCR systems to process 93 patient samples per run.
The panel's developers at UPenn hope to validate and commercialize a non-invasive assay through a startup called Chip Diagnostics.
Droplet digital PCR tests for SARS-CoV-2 can potentially detect the very low viral loads seen in asymptomatic and convalescent cases.
The technology uses single-cell droplet digital PCR to analyze maternal blood cell populations that have been enriched for fetal cells by MACS.
On Monday Qiagen reiterated its preliminary 2019 earnings figures and addressed an investor's wrath, while Guardant Health highlighted its cancer testing plans.
The firm saw modest growth across both of its business segments and double-digit growth in its droplet digital PCR product line.
The life science segment saw strong sales in Droplet Digital PCR offset by sales the firm's process media product line.
